JP6915946B2 - 過剰な毛髪脱落の検出及び処置 - Google Patents

過剰な毛髪脱落の検出及び処置 Download PDF

Info

Publication number
JP6915946B2
JP6915946B2 JP2017542212A JP2017542212A JP6915946B2 JP 6915946 B2 JP6915946 B2 JP 6915946B2 JP 2017542212 A JP2017542212 A JP 2017542212A JP 2017542212 A JP2017542212 A JP 2017542212A JP 6915946 B2 JP6915946 B2 JP 6915946B2
Authority
JP
Japan
Prior art keywords
range
day
daily
oral
hair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017542212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533265A5 (enExample
JP2017533265A (ja
Inventor
ロドニー シンクレア
ロドニー シンクレア
Original Assignee
サムソン クリニカル プロプライエタリー リミテッド
サムソン クリニカル プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55856287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6915946(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014904327A external-priority patent/AU2014904327A0/en
Application filed by サムソン クリニカル プロプライエタリー リミテッド, サムソン クリニカル プロプライエタリー リミテッド filed Critical サムソン クリニカル プロプライエタリー リミテッド
Publication of JP2017533265A publication Critical patent/JP2017533265A/ja
Publication of JP2017533265A5 publication Critical patent/JP2017533265A5/ja
Application granted granted Critical
Publication of JP6915946B2 publication Critical patent/JP6915946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2017542212A 2014-10-29 2015-10-29 過剰な毛髪脱落の検出及び処置 Active JP6915946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014904327A AU2014904327A0 (en) 2014-10-29 Detection and treatment of excessive hair shedding
AU2014904327 2014-10-29
PCT/AU2015/050682 WO2016065426A1 (en) 2014-10-29 2015-10-29 Detection and treatment of excessive hair shedding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020067194A Division JP2020109127A (ja) 2014-10-29 2020-04-03 過剰な毛髪脱落の検出及び処置

Publications (3)

Publication Number Publication Date
JP2017533265A JP2017533265A (ja) 2017-11-09
JP2017533265A5 JP2017533265A5 (enExample) 2018-09-27
JP6915946B2 true JP6915946B2 (ja) 2021-08-11

Family

ID=55856287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017542212A Active JP6915946B2 (ja) 2014-10-29 2015-10-29 過剰な毛髪脱落の検出及び処置
JP2020067194A Pending JP2020109127A (ja) 2014-10-29 2020-04-03 過剰な毛髪脱落の検出及び処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020067194A Pending JP2020109127A (ja) 2014-10-29 2020-04-03 過剰な毛髪脱落の検出及び処置

Country Status (11)

Country Link
US (2) US10226462B2 (enExample)
EP (2) EP3626244B1 (enExample)
JP (2) JP6915946B2 (enExample)
KR (2) KR20240011239A (enExample)
CN (2) CN107106560A (enExample)
AU (4) AU2015337807B2 (enExample)
CA (2) CA3209849A1 (enExample)
ES (2) ES2773467T3 (enExample)
NZ (1) NZ732075A (enExample)
SG (2) SG10202002705YA (enExample)
WO (1) WO2016065426A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106560A (zh) 2014-10-29 2017-08-29 萨姆森临床私人有限公司 毛发过度脱落的检测和治疗
WO2018093465A1 (en) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US20180189976A1 (en) 2016-12-29 2018-07-05 Michal Kasprzak Analysis unit and system for assessment of hair condition
SG11202000124PA (en) * 2017-07-12 2020-02-27 Samson Clinical Pty Ltd Promoting hair growth and treatment of hair loss or excessive hair shedding
US20220079911A1 (en) * 2018-09-13 2022-03-17 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
CN109674762A (zh) * 2019-03-05 2019-04-26 南京正大天晴制药有限公司 一种度他雄胺及治疗脱发的组合物胶囊
CN110478450B (zh) * 2019-10-09 2021-04-13 北海鑫臻药业有限公司 一种治疗阿尔茨海默病的药物组合物及其应用
CN111110721A (zh) * 2020-01-19 2020-05-08 朱炜 一种毛发防脱再生的复合制剂及其使用方法
CN115136191B (zh) * 2020-02-27 2025-03-25 松下知识产权经营株式会社 图像处理装置及图像处理方法
CA3233426A1 (en) * 2021-09-29 2023-04-06 Animesh SINHA Hair loss therapy
US11744788B2 (en) * 2021-10-27 2023-09-05 James D. Welch Method of encouraging growth and regrowth of hair in human males technical area
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
WO2025048828A1 (en) * 2023-09-01 2025-03-06 Follea International Compositions and methods for an oral supplement to oral minoxidil for the treatment of alopecia
US20250213594A1 (en) * 2023-12-27 2025-07-03 Inventage Lab Inc. Novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997643A (en) 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
WO1992008705A1 (en) * 1990-11-14 1992-05-29 The Upjohn Company 5-fluoro-2,4,6-pyrimidinetriamine compounds
US5407944A (en) 1993-02-19 1995-04-18 Goldman; Boris E. Compositions and methods for promoting hair growth
GB2314019B (en) * 1996-06-10 2000-03-15 Bio Scient Ltd The use of L-Lysine in the treatment of hair loss
AU2406299A (en) 1998-02-12 1999-08-30 Centrapharm Inc. Sublingual drug formulations having combined rapid onset of action and long lasting therapeutic effect
JP2000038340A (ja) 1998-05-20 2000-02-08 Kumahiro Miyama 育毛剤および食品
JP2003012542A (ja) 2001-06-26 2003-01-15 Toray Ind Inc 発毛促進剤
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
JPWO2006038315A1 (ja) 2004-10-07 2008-07-31 株式会社サンギ 経皮・経粘膜吸収製剤
US20080064765A1 (en) 2006-09-11 2008-03-13 Jacob Birnbaum Novel hair growth compositions and methods for treating hair loss or related claims
WO2008067158A2 (en) * 2006-11-13 2008-06-05 Auxagen, Inc. METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
DK2344198T3 (da) * 2008-09-27 2020-11-30 Jina Pharmaceuticals Inc Lipidbaserede farmaceutiske præparater til topisk anvendelse
US8691518B2 (en) * 2010-09-24 2014-04-08 Global Life Science Partners Limited Systems and methods for predicting response to minoxidil for the treatment of androgenetic alopecia
EP2510930A1 (en) 2011-04-15 2012-10-17 Bionanoplus, S.L. Nanoparticles comprising half esters of poly (methyl vinyl ether-co-maleic anhydride) and uses thereof
AU2011100917B4 (en) * 2011-07-26 2013-05-02 Sinclair, Rodney Daniel Professor Treatment of male and female androgenetic alopecia with oral minoxidil either alone or in combination with antiandrogens
WO2013181487A2 (en) 2012-05-31 2013-12-05 Stiefel Laboratories, Inc. Method of treating
CN107106560A (zh) 2014-10-29 2017-08-29 萨姆森临床私人有限公司 毛发过度脱落的检测和治疗
US9561224B1 (en) 2015-05-27 2017-02-07 Moshe Rogosnitzky Methods and compositions for treating androgenetic alopecia
SG11202000124PA (en) 2017-07-12 2020-02-27 Samson Clinical Pty Ltd Promoting hair growth and treatment of hair loss or excessive hair shedding

Also Published As

Publication number Publication date
HK1243641A1 (en) 2018-07-20
JP2020109127A (ja) 2020-07-16
EP3212192A4 (en) 2018-07-04
KR20170102214A (ko) 2017-09-08
CA3209849A1 (en) 2016-05-06
US10226462B2 (en) 2019-03-12
CA3003940A1 (en) 2016-05-06
WO2016065426A1 (en) 2016-05-06
AU2015337807B2 (en) 2017-05-04
EP3626244B1 (en) 2023-06-07
SG11201703424WA (en) 2017-05-30
AU2017210523A1 (en) 2017-08-17
EP3212192B1 (en) 2019-11-20
US20190192513A1 (en) 2019-06-27
AU2017210523B2 (en) 2018-11-15
EP3212192A1 (en) 2017-09-06
CN115998740A (zh) 2023-04-25
CN107106560A (zh) 2017-08-29
ES2952159T3 (es) 2023-10-27
KR20240011239A (ko) 2024-01-25
US11116770B2 (en) 2021-09-14
EP3626244A1 (en) 2020-03-25
AU2018279055A1 (en) 2019-01-17
AU2020203695A1 (en) 2020-06-25
AU2015337807A1 (en) 2017-04-13
JP2017533265A (ja) 2017-11-09
KR102625061B1 (ko) 2024-01-16
ES2773467T3 (es) 2020-07-13
SG10202002705YA (en) 2020-05-28
NZ732075A (en) 2022-09-30
AU2020203695B2 (en) 2021-09-02
CA3003940C (en) 2023-10-10
US20170333432A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
JP6915946B2 (ja) 過剰な毛髪脱落の検出及び処置
Asghar et al. Telogen effluvium: a review of the literature
Glynis A double-blind, placebo-controlled study evaluating the efficacy of an oral supplement in women with self-perceived thinning hair
Lucky et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
Goldberg et al. Alopecia: Kids are not just little people
RU2431485C2 (ru) Способ лечения нарушений роста волос, таких как облысение по женскому типу, и применяемые в нем композиции
JP4469617B2 (ja) 育毛料
Sinclair et al. Fast facts: disorders of the hair and scalp
HK40023042A (en) Oral minoxidil for the treatment of alopecia areata
HK40023042B (en) Oral minoxidil for the treatment of alopecia areata
HK1243641B (en) Oral minoxidil for the treatment of telogen effluvium
Rebora Changes in Growth and Distribution of Hair Associated with Psychotropic Drug Use: Incidence and Mechanisms
Islam et al. A guide to diagnosis and management of hypertrichosis
Hamzeh et al. Common Causes of Hair Loss
Sinha et al. Hair Disorders in Females
de Oliveira Community Pharmacy and Hospital Pharmacy Internship Reports and Monograph" Counseling for Androgenetic Alopecia-The Pharmacist's Role"
Roberts Geriatric hair and scalp disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200407

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200512

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200512

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20201124

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210326

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210511

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210615

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210712

R150 Certificate of patent or registration of utility model

Ref document number: 6915946

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250